Fase III que utiliza Nab-Paclitaxel + Carboplatino y Pembrolizumab en NSCLC escamoso. El hazard ratio favorece a Nab paclitaxel en el análisis de subgrupos.
1) Recent immunotherapy advances for advanced NSCLC include the approval of pembrolizumab as a first-line treatment for patients with PD-L1 expression ≥50% based on results from the KEYNOTE-024 trial showing improved progression-free and overall survival compared to chemotherapy.
2) The Phase III KEYNOTE-407 trial found that combining pembrolizumab with chemotherapy improved progression-free survival compared to chemotherapy alone in patients with untreated metastatic squamous NSCLC, regardless of PD-L1 expression level.
3) Combining chemotherapy with immunotherapy may enhance the immune response by increasing antigen presentation, disrupting immune evasion mechanisms, and improving outcomes compared to chemotherapy or immunotherapy alone.
molecular biology and Target therapy in lung cancerRikin Hasnani
This document summarizes molecular biology and targeted therapies in lung cancer. It discusses that lung cancer is a leading cause of cancer death worldwide. Historically, lung cancers were classified by histology alone, but it is now known they are driven by specific mutations. Key driver mutations were discovered in the EGFR, ALK, KRAS genes. These mutations activate intracellular signaling pathways like RAS/RAF/MEK/ERK and regulate cell growth. Targeted therapies like EGFR TKIs erlotinib and gefitinib or the ALK inhibitor crizotinib have significantly improved outcomes for patients with specific driver mutations. However, resistance often develops through secondary mutations like T790M, requiring new
The document summarizes clinical updates and advances in the treatment of non-small cell lung cancer (NSCLC). It discusses the incidence, subtypes and staging of NSCLC and recommendations for adjuvant therapy, targeted therapy and treatment of metastatic disease. It also reviews results from randomized trials of adjuvant chemotherapy showing improved survival compared to observation alone.
EGFR mutations are present in 10-20% of Caucasian and 40-60% of Asian patients with NSCLC. First-generation EGFR TKIs such as gefitinib and erlotinib are the standard of care for patients with EGFR mutations. The FLAURA trial found that the third-generation EGFR TKI osimertinib significantly improved progression-free survival compared to gefitinib or erlotinib as a first-line treatment for EGFR mutant NSCLC. Osimertinib also showed benefits for patients with CNS metastases. However, combination of first-generation EGFR TKIs with chemotherapy may provide further benefits like improved overall response rate, progression-free
The document summarizes several targeted therapies for breast cancer including monoclonal antibodies (trastuzumab, ado-trastuzumab emtansine, fam-trastuzumab deruxtecan, pertuzumab, margetuximab-cmkb), antibody-drug conjugates (ado-trastuzumab emtansine, fam-trastuzumab deruxtecan, sacituzumab govitecan), immune checkpoint inhibitors (pembrolizumab, atezolizumab), and PARP inhibitors (olaparib). It provides details on the mechanisms of action, FDA-approved indications, dosing schedules, and safety profiles of these targeted therapies.
Fase III que utiliza Nab-Paclitaxel + Carboplatino y Pembrolizumab en NSCLC escamoso. El hazard ratio favorece a Nab paclitaxel en el análisis de subgrupos.
1) Recent immunotherapy advances for advanced NSCLC include the approval of pembrolizumab as a first-line treatment for patients with PD-L1 expression ≥50% based on results from the KEYNOTE-024 trial showing improved progression-free and overall survival compared to chemotherapy.
2) The Phase III KEYNOTE-407 trial found that combining pembrolizumab with chemotherapy improved progression-free survival compared to chemotherapy alone in patients with untreated metastatic squamous NSCLC, regardless of PD-L1 expression level.
3) Combining chemotherapy with immunotherapy may enhance the immune response by increasing antigen presentation, disrupting immune evasion mechanisms, and improving outcomes compared to chemotherapy or immunotherapy alone.
molecular biology and Target therapy in lung cancerRikin Hasnani
This document summarizes molecular biology and targeted therapies in lung cancer. It discusses that lung cancer is a leading cause of cancer death worldwide. Historically, lung cancers were classified by histology alone, but it is now known they are driven by specific mutations. Key driver mutations were discovered in the EGFR, ALK, KRAS genes. These mutations activate intracellular signaling pathways like RAS/RAF/MEK/ERK and regulate cell growth. Targeted therapies like EGFR TKIs erlotinib and gefitinib or the ALK inhibitor crizotinib have significantly improved outcomes for patients with specific driver mutations. However, resistance often develops through secondary mutations like T790M, requiring new
The document summarizes clinical updates and advances in the treatment of non-small cell lung cancer (NSCLC). It discusses the incidence, subtypes and staging of NSCLC and recommendations for adjuvant therapy, targeted therapy and treatment of metastatic disease. It also reviews results from randomized trials of adjuvant chemotherapy showing improved survival compared to observation alone.
EGFR mutations are present in 10-20% of Caucasian and 40-60% of Asian patients with NSCLC. First-generation EGFR TKIs such as gefitinib and erlotinib are the standard of care for patients with EGFR mutations. The FLAURA trial found that the third-generation EGFR TKI osimertinib significantly improved progression-free survival compared to gefitinib or erlotinib as a first-line treatment for EGFR mutant NSCLC. Osimertinib also showed benefits for patients with CNS metastases. However, combination of first-generation EGFR TKIs with chemotherapy may provide further benefits like improved overall response rate, progression-free
The document summarizes several targeted therapies for breast cancer including monoclonal antibodies (trastuzumab, ado-trastuzumab emtansine, fam-trastuzumab deruxtecan, pertuzumab, margetuximab-cmkb), antibody-drug conjugates (ado-trastuzumab emtansine, fam-trastuzumab deruxtecan, sacituzumab govitecan), immune checkpoint inhibitors (pembrolizumab, atezolizumab), and PARP inhibitors (olaparib). It provides details on the mechanisms of action, FDA-approved indications, dosing schedules, and safety profiles of these targeted therapies.
This document discusses various targeted cancer therapies including monoclonal antibodies, small molecule inhibitors, and other targeted agents. It describes key targets of these therapies such as protein kinases, growth factor receptors, angiogenesis pathways, and nuclear factors. Specific drugs are discussed that target ABL, EGFR, VEGFR, mTOR, MAPK pathways, and the proteasome. Resistance mechanisms and combination approaches are also mentioned.
The document discusses two families of cyclin-dependent kinase inhibitors (CDKIs) - the CIP family and the INK family. The CIP family includes proteins like p21cip, p27kip2, and p57kip2 that inhibit cyclin A-CDK2 activity and must be degraded for DNA replication to begin. The INK family includes proteins like p16 that specifically interact with and inhibit CDK4/CDK6, blocking their interaction with cyclin D, phosphorylation of Rb protein, and entry into the S phase of the cell cycle. Mutation of the INK4 protein p16 can lead to tumor development.
Principles of medical_oncology dr. varunVarun Goel
- The document discusses several key principles of medical oncology including that cancer treatment is multidisciplinary, early stage cancers are more curable than late stage, and the best treatment is often found in clinical trials.
- It describes the basic tenets of chemotherapy including that it can be used for induction treatment of advanced cancers or as adjuvant treatment after local therapy to treat high risk of recurrence. The intent of chemotherapy can be curative or palliative.
- Several models of tumor growth and response to chemotherapy are explained including the Skipper-Wilcox model, concepts of combination chemotherapy, and the Goldie-Coldman model regarding emergence of drug resistance with increased tumor size.
Anjali Saqi, MD, MBA, and Geoffrey R. Oxnard, MD, prepared useful practice aids pertaining to lung cancer for this CME/MOC activity titled "Navigating the Complexities of Molecular Testing for EGFR Mutations to Guide Treatment Selection in Lung Cancer: Evidence, Practicalities, and Implications for Pathologists." For the full presentation, monograph, complete CME/MOC information, and to apply for credit, please visit us at http://bit.ly/2DkXD65. CME/MOC credit will be available until November 28, 2019.
Lung cancer is a major cause of cancer deaths with approximately 80% of cases accounting to nonsmall cell lung cancer (NSCLC) . In NSCLC target therapy, epidermal growth factor receptor (EGFR) is a promising candidate.
This document discusses tyrosine kinase inhibitors and their role in cancer therapy. It begins by introducing tyrosine kinases and their importance in cellular signaling pathways. Tyrosine kinases are implicated in cancer development and progression. The document then discusses the classification, structure, and mechanisms of tyrosine kinase receptors. It provides examples of FDA-approved tyrosine kinase inhibitors for various cancers. The document discusses strategies for inhibiting EGFR signaling, including monoclonal antibodies and small molecule tyrosine kinase inhibitors. It also provides information on trastuzumab and its role and use for HER2-positive breast cancer.
Recent advances in targeted therapy for metastatic lung cancerAlok Gupta
This document discusses recent advances in targeted therapy for metastatic lung cancer. It summarizes key findings from several clinical trials evaluating third-generation EGFR TKIs like osimertinib for patients with EGFR mutation-positive NSCLC. The document highlights that osimertinib provides significantly longer progression-free survival compared to earlier generation EGFR TKIs, with a median PFS of 18.9 months versus 10.2 months. Osimertinib also demonstrated a higher objective response rate and longer duration of response. Benefits were consistent across patient subgroups.
Diagnostic approach to neuroendocrine tumors of lungHajra Mehdi
This document provides an overview of the diagnostic approach to neuroendocrine tumors of the lung. It discusses the WHO classification of lung neuroendocrine tumors and covers the various types including typical carcinoid tumor, atypical carcinoid tumor, large cell neuroendocrine carcinoma, small cell carcinoma, and mixed or composite tumors. For each tumor type, the presentation, histopathology, immunohistochemistry, differential diagnosis, and prognosis are summarized. The document also discusses special considerations for small biopsies/cytology specimens and cases.
1) Targeted kinase inhibitors such as sorafenib show promise in treating radioactive iodine refractory thyroid cancer, with sorafenib demonstrating a partial response rate of 36% and clinical benefit in 82% of patients in one study.
2) Management of radioactive iodine refractory thyroid cancer involves local therapies when possible and enrollment in clinical trials of small molecule tyrosine kinase inhibitors like sorafenib, which target pathways important in thyroid cancer signaling and growth.
3) Guidelines recommend targeted kinase inhibitors as first-line treatment for radioactive iodine refractory thyroid cancer based on their improved efficacy over chemotherapy and ability to potentially prolong progression-free and overall survival.
What are the latest treatment advances for HER2-positive metastatic breast cancer? Eric Winer, MD, director of the Breast Cancer Program in the Susan F. Smith Center for Women's Cancers, discusses some of the latest research and treatment options.
This presentation was originally given as part of the 2015 Metastatic Breast Cancer Forum, held on October 17 at Dana-Farber Cancer Institute in Boston, Mass.
For more information, visit www.susanfsmith.org
This document summarizes information about immunotherapy for non-small cell lung cancer (NSCLC). It provides data on key clinical trials that evaluated immunotherapy drugs like nivolumab and pembrolizumab in previously treated NSCLC. It shows the efficacy results including overall survival benefits from these trials compared to chemotherapy. Long-term survival outcomes are also presented from pooled analyses of nivolumab trials with over 3 years of follow-up data.
This document provides an overview of the management of non-small cell lung cancer (NSCLC). It discusses the anatomy of the lung and lymph node mapping. The clinical features, diagnostic workup including imaging and staging are covered. The various treatment approaches for early, locally advanced and metastatic NSCLC including surgery, radiation therapy, chemotherapy and targeted therapy are summarized. Techniques for radiation therapy planning and delivery such as 3D conformal radiation therapy, stereotactic body radiation therapy, proton beam therapy and brachytherapy are also outlined.
Pathology and Oncology Expert Perspectives in the Management of Triple-Negati...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck, presented by Dr. Ira Bleiweiss, Chief of Breast Pathology at the University of Pennsylvania, and Dr. Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, will feature expert pathology and oncology perspectives on the management of triple-negative breast cancer (TNBC), including case explorations and insights into frequently asked questions. Register today to hear these expert perspectives!
Statement of Need
Triple-negative breast cancer (TNBC) is an aggressive disease that accounts for approximately 10% to 15% of breast cancer diagnoses and is characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). TNBC is more common in Black women and in women under the age of 40 (ACS, 2023). Compared with other subtypes of invasive breast cancer, TNBC has high rates of metastasis and a poor prognosis. Due to the lack of hormone and receptor targets, therapeutic options are limited, and prognostication and treatment selection are complicated by the heterogeneity of the disease (Yang et al, 2022). In this live webinar, Dr. Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and Dr. Ira Bleiweiss, Chief of Breast Pathology at the Hospital of the University of Pennsylvania, will provide expert oncology and pathology perspectives on evidence-based strategies for diagnosis, treatment, and adverse event management for patients with TNBC.
TARGET AUDIENCE
Medical oncologists, surgical oncologists, radiation oncologists, pathologists, nurse practitioners, physician assistants, oncology nurses, and other health care professionals involved in the treatment of patients with triple-negative breast cancer (TNBC).
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
Evaluate receptor and expression status for prognostication and treatment selection in TNBC
Differentiate the pathological characteristics of the various types of TNBC
Select optimal therapy for TNBC based on shared goals, biomarker testing, and clinical data on novel therapies
Discuss strategies for timely recognition and mitigation of adverse events associated with novel TNBC therapies
This deals with the current paradigm of treatment of osteosarcoma. It is an honest effort to clear the prevailing confusion in the treatment of osteosarcoma. I would be happy to get anyone
Chair and Presenter, Jonathan D. Spicer, MD, PhD, FRCSC, Sara Najmeh, MD, and Paula A. Ugalde Figueroa, MD, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC activity titled “Neoadjuvant, Adjuvant, or Both: How to Solve the Puzzle of Perioperative Immunotherapy, Individualize Treatment Plans, and Improve Cure Rates in Resectable NSCLC.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3K8tKH9. CME/MOC credit will be available until June 5, 2024.
Dr. Patrick Hwu presents the latest information on immunotherapies for melanoma at the MRF's Patient Symposium at MD Anderson Cancer Center on January 31, 2015.
This document provides an overview of recent advances in lung cancer research. It discusses the types of lung cancer and treatments such as chemotherapy, immunotherapy, and targeted therapies. New discoveries include approval of the first KRAS inhibitor drug and combinations of chemotherapy with drugs that inhibit DNA repair. Ongoing areas of research focus on biomarkers, immunotherapy, liquid biopsies, robotics for surgery, and stereotactic radiation. The future for lung cancer treatment is promising with decreasing mortality rates resulting from new targeted therapies and increased use of screening.
Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinibseayat1103
This document discusses a clinical trial comparing the efficacy of erlotinib and gefitinib for the treatment of non-small cell lung cancer. The trial found that both erlotinib and gefitinib showed efficacy in NSCLC patients with EGFR mutations, with erlotinib demonstrating a median progression-free survival of 10.8 months compared to 5.4 months for standard chemotherapy in EGFR mutation-positive patients. Subsequent studies confirmed the superior efficacy of both erlotinib and gefitinib in NSCLC patients with EGFR mutations, particularly those with exon 19 deletions or L858R mutations. The document concludes by discussing the current NCCN guidelines for use of erlotinib and
Geoffrey Oxnard, MD, discusses the latest research in targeted therapies and molecular testing to treat lung cancer.
This presentation was originally given as part of "Living with Lung Cancer: A Forum for Patients and Caregivers" on Nov. 14, 2015 at Dana-Farber Cancer Institute in Boston, Mass.
This document discusses various targeted cancer therapies including monoclonal antibodies, small molecule inhibitors, and other targeted agents. It describes key targets of these therapies such as protein kinases, growth factor receptors, angiogenesis pathways, and nuclear factors. Specific drugs are discussed that target ABL, EGFR, VEGFR, mTOR, MAPK pathways, and the proteasome. Resistance mechanisms and combination approaches are also mentioned.
The document discusses two families of cyclin-dependent kinase inhibitors (CDKIs) - the CIP family and the INK family. The CIP family includes proteins like p21cip, p27kip2, and p57kip2 that inhibit cyclin A-CDK2 activity and must be degraded for DNA replication to begin. The INK family includes proteins like p16 that specifically interact with and inhibit CDK4/CDK6, blocking their interaction with cyclin D, phosphorylation of Rb protein, and entry into the S phase of the cell cycle. Mutation of the INK4 protein p16 can lead to tumor development.
Principles of medical_oncology dr. varunVarun Goel
- The document discusses several key principles of medical oncology including that cancer treatment is multidisciplinary, early stage cancers are more curable than late stage, and the best treatment is often found in clinical trials.
- It describes the basic tenets of chemotherapy including that it can be used for induction treatment of advanced cancers or as adjuvant treatment after local therapy to treat high risk of recurrence. The intent of chemotherapy can be curative or palliative.
- Several models of tumor growth and response to chemotherapy are explained including the Skipper-Wilcox model, concepts of combination chemotherapy, and the Goldie-Coldman model regarding emergence of drug resistance with increased tumor size.
Anjali Saqi, MD, MBA, and Geoffrey R. Oxnard, MD, prepared useful practice aids pertaining to lung cancer for this CME/MOC activity titled "Navigating the Complexities of Molecular Testing for EGFR Mutations to Guide Treatment Selection in Lung Cancer: Evidence, Practicalities, and Implications for Pathologists." For the full presentation, monograph, complete CME/MOC information, and to apply for credit, please visit us at http://bit.ly/2DkXD65. CME/MOC credit will be available until November 28, 2019.
Lung cancer is a major cause of cancer deaths with approximately 80% of cases accounting to nonsmall cell lung cancer (NSCLC) . In NSCLC target therapy, epidermal growth factor receptor (EGFR) is a promising candidate.
This document discusses tyrosine kinase inhibitors and their role in cancer therapy. It begins by introducing tyrosine kinases and their importance in cellular signaling pathways. Tyrosine kinases are implicated in cancer development and progression. The document then discusses the classification, structure, and mechanisms of tyrosine kinase receptors. It provides examples of FDA-approved tyrosine kinase inhibitors for various cancers. The document discusses strategies for inhibiting EGFR signaling, including monoclonal antibodies and small molecule tyrosine kinase inhibitors. It also provides information on trastuzumab and its role and use for HER2-positive breast cancer.
Recent advances in targeted therapy for metastatic lung cancerAlok Gupta
This document discusses recent advances in targeted therapy for metastatic lung cancer. It summarizes key findings from several clinical trials evaluating third-generation EGFR TKIs like osimertinib for patients with EGFR mutation-positive NSCLC. The document highlights that osimertinib provides significantly longer progression-free survival compared to earlier generation EGFR TKIs, with a median PFS of 18.9 months versus 10.2 months. Osimertinib also demonstrated a higher objective response rate and longer duration of response. Benefits were consistent across patient subgroups.
Diagnostic approach to neuroendocrine tumors of lungHajra Mehdi
This document provides an overview of the diagnostic approach to neuroendocrine tumors of the lung. It discusses the WHO classification of lung neuroendocrine tumors and covers the various types including typical carcinoid tumor, atypical carcinoid tumor, large cell neuroendocrine carcinoma, small cell carcinoma, and mixed or composite tumors. For each tumor type, the presentation, histopathology, immunohistochemistry, differential diagnosis, and prognosis are summarized. The document also discusses special considerations for small biopsies/cytology specimens and cases.
1) Targeted kinase inhibitors such as sorafenib show promise in treating radioactive iodine refractory thyroid cancer, with sorafenib demonstrating a partial response rate of 36% and clinical benefit in 82% of patients in one study.
2) Management of radioactive iodine refractory thyroid cancer involves local therapies when possible and enrollment in clinical trials of small molecule tyrosine kinase inhibitors like sorafenib, which target pathways important in thyroid cancer signaling and growth.
3) Guidelines recommend targeted kinase inhibitors as first-line treatment for radioactive iodine refractory thyroid cancer based on their improved efficacy over chemotherapy and ability to potentially prolong progression-free and overall survival.
What are the latest treatment advances for HER2-positive metastatic breast cancer? Eric Winer, MD, director of the Breast Cancer Program in the Susan F. Smith Center for Women's Cancers, discusses some of the latest research and treatment options.
This presentation was originally given as part of the 2015 Metastatic Breast Cancer Forum, held on October 17 at Dana-Farber Cancer Institute in Boston, Mass.
For more information, visit www.susanfsmith.org
This document summarizes information about immunotherapy for non-small cell lung cancer (NSCLC). It provides data on key clinical trials that evaluated immunotherapy drugs like nivolumab and pembrolizumab in previously treated NSCLC. It shows the efficacy results including overall survival benefits from these trials compared to chemotherapy. Long-term survival outcomes are also presented from pooled analyses of nivolumab trials with over 3 years of follow-up data.
This document provides an overview of the management of non-small cell lung cancer (NSCLC). It discusses the anatomy of the lung and lymph node mapping. The clinical features, diagnostic workup including imaging and staging are covered. The various treatment approaches for early, locally advanced and metastatic NSCLC including surgery, radiation therapy, chemotherapy and targeted therapy are summarized. Techniques for radiation therapy planning and delivery such as 3D conformal radiation therapy, stereotactic body radiation therapy, proton beam therapy and brachytherapy are also outlined.
Pathology and Oncology Expert Perspectives in the Management of Triple-Negati...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck, presented by Dr. Ira Bleiweiss, Chief of Breast Pathology at the University of Pennsylvania, and Dr. Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, will feature expert pathology and oncology perspectives on the management of triple-negative breast cancer (TNBC), including case explorations and insights into frequently asked questions. Register today to hear these expert perspectives!
Statement of Need
Triple-negative breast cancer (TNBC) is an aggressive disease that accounts for approximately 10% to 15% of breast cancer diagnoses and is characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). TNBC is more common in Black women and in women under the age of 40 (ACS, 2023). Compared with other subtypes of invasive breast cancer, TNBC has high rates of metastasis and a poor prognosis. Due to the lack of hormone and receptor targets, therapeutic options are limited, and prognostication and treatment selection are complicated by the heterogeneity of the disease (Yang et al, 2022). In this live webinar, Dr. Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and Dr. Ira Bleiweiss, Chief of Breast Pathology at the Hospital of the University of Pennsylvania, will provide expert oncology and pathology perspectives on evidence-based strategies for diagnosis, treatment, and adverse event management for patients with TNBC.
TARGET AUDIENCE
Medical oncologists, surgical oncologists, radiation oncologists, pathologists, nurse practitioners, physician assistants, oncology nurses, and other health care professionals involved in the treatment of patients with triple-negative breast cancer (TNBC).
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
Evaluate receptor and expression status for prognostication and treatment selection in TNBC
Differentiate the pathological characteristics of the various types of TNBC
Select optimal therapy for TNBC based on shared goals, biomarker testing, and clinical data on novel therapies
Discuss strategies for timely recognition and mitigation of adverse events associated with novel TNBC therapies
This deals with the current paradigm of treatment of osteosarcoma. It is an honest effort to clear the prevailing confusion in the treatment of osteosarcoma. I would be happy to get anyone
Chair and Presenter, Jonathan D. Spicer, MD, PhD, FRCSC, Sara Najmeh, MD, and Paula A. Ugalde Figueroa, MD, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC activity titled “Neoadjuvant, Adjuvant, or Both: How to Solve the Puzzle of Perioperative Immunotherapy, Individualize Treatment Plans, and Improve Cure Rates in Resectable NSCLC.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3K8tKH9. CME/MOC credit will be available until June 5, 2024.
Dr. Patrick Hwu presents the latest information on immunotherapies for melanoma at the MRF's Patient Symposium at MD Anderson Cancer Center on January 31, 2015.
This document provides an overview of recent advances in lung cancer research. It discusses the types of lung cancer and treatments such as chemotherapy, immunotherapy, and targeted therapies. New discoveries include approval of the first KRAS inhibitor drug and combinations of chemotherapy with drugs that inhibit DNA repair. Ongoing areas of research focus on biomarkers, immunotherapy, liquid biopsies, robotics for surgery, and stereotactic radiation. The future for lung cancer treatment is promising with decreasing mortality rates resulting from new targeted therapies and increased use of screening.
Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinibseayat1103
This document discusses a clinical trial comparing the efficacy of erlotinib and gefitinib for the treatment of non-small cell lung cancer. The trial found that both erlotinib and gefitinib showed efficacy in NSCLC patients with EGFR mutations, with erlotinib demonstrating a median progression-free survival of 10.8 months compared to 5.4 months for standard chemotherapy in EGFR mutation-positive patients. Subsequent studies confirmed the superior efficacy of both erlotinib and gefitinib in NSCLC patients with EGFR mutations, particularly those with exon 19 deletions or L858R mutations. The document concludes by discussing the current NCCN guidelines for use of erlotinib and
Geoffrey Oxnard, MD, discusses the latest research in targeted therapies and molecular testing to treat lung cancer.
This presentation was originally given as part of "Living with Lung Cancer: A Forum for Patients and Caregivers" on Nov. 14, 2015 at Dana-Farber Cancer Institute in Boston, Mass.
1. Receptor tyrosine kinases (RTKs) drive key cancer pathways and can be exploited as therapeutic targets, as shown by drugs like imatinib that inhibit mutated kinases in cancers.
2. RTK inhibitors have shown efficacy against cancers dependent on single kinases, but resistance often emerges through secondary mutations or bypass pathways.
3. Effective combination therapies are needed to overcome resistance, such as combining RTK inhibitors with other drugs that block downstream or bypass pathways.
Acquired Resistance to Targeted Therapy in EGFR and ALK-Positive Lung Cancer:...H. Jack West
This is a presentation I did for a meeting on new general management of acquired resistance in 2014, including the concept of local therapy for limited progression, and new treatment approaches and new agents for this setting. It features discussion of several of the most important trials.
West xcenda molec testing sf oct 2011 revised finalH. Jack West
The document discusses the importance of molecular testing in advanced non-small cell lung cancer (NSCLC) to identify subsets of patients that may benefit from targeted therapies. It summarizes several studies that showed significantly improved outcomes with EGFR tyrosine kinase inhibitors compared to chemotherapy in patients with EGFR mutations. Additionally, KRAS mutations were found to confer resistance to EGFR inhibitors in NSCLC.
This document summarizes new targeted therapies for non-small cell lung cancers (NSCLCs). It discusses targeted agents for driver mutations in adenocarcinomas, including crizotinib for ALK rearrangements and ROS1 fusions, selective EGFR inhibitors, and investigational therapies targeting KRAS, BRAF, HER2 and MET alterations. Crizotinib improves outcomes over chemotherapy for ALK-positive NSCLC. Second generation ALK and EGFR inhibitors show responses in patients resistant to first-line therapies. The document also briefly mentions targeted approaches for squamous cell carcinomas but notes driver mutations are less common in this histology.
This document provides an overview and preliminary assessment of AstraZeneca's oncology portfolio. It summarizes their current approved oncology drugs, key disease areas and scientific platforms. It also outlines their extensive clinical development pipeline, with 13 late-stage programs, 17 phase 3 programs, 10 phase 2 programs and 26 phase 1 programs. Many of these programs are expected to file for approval in late 2016 and 2017, creating significant commercialization opportunities but also resource requirements to optimize launches. The oncology landscape is highly competitive, especially in AstraZeneca's core areas, and will continue expanding with new treatment classes.
This document summarizes the evolution of systemic therapy for non-small cell lung cancer (NSCLC) from empiric chemotherapy to molecularly-driven approaches. It discusses:
1) How histological classification is now necessary for treatment decisions, as different chemotherapy regimens have different efficacy depending on adenocarcinoma or squamous cell carcinoma subtype.
2) How maintenance therapy and extended duration of therapy have shown survival benefits compared to stopping treatment after a set number of cycles.
3) The need for molecular classification of NSCLC to guide targeted therapies, including determining EGFR and ALK status to select appropriate first-line tyrosine kinase inhibitors or chemotherapy. Ongoing research aims to identify more driver mutations
1) EGFR mutations are found in 10-30% of NSCLC cases and are associated with response to EGFR TKIs as first-line treatment.
2) Several studies including IPASS, EURTAC and LUX-Lung 3 have shown superior PFS for first-generation EGFR TKIs like gefitinib and erlotinib and the second-generation TKI afatinib compared to platinum-based chemotherapy as first-line treatment for EGFR mutation-positive NSCLC.
3) Meta-analyses of these studies demonstrate improved PFS for EGFR TKIs compared to chemotherapy in EGFR mutation-positive NSCLC, though OS is generally similar between the treatments
This document discusses evolving strategies for the personalized treatment of non-small cell lung cancer (NSCLC). It covers histological and molecular subtypes of NSCLC, key clinical trials of the EGFR tyrosine kinase inhibitor gefitinib, mechanisms of acquired resistance to EGFR TKIs, and approaches to managing resistance. A phase IV study showed gefitinib was effective first-line therapy for Caucasian patients with EGFR mutation-positive NSCLC, with a 69.8% response rate and favorable progression-free and overall survival. Exploratory analyses found plasma samples could accurately assess EGFR mutation status when tumor tissue was unavailable. The document reviews strategies for treating systemic and central nervous system progression after acquiring resistance to EGFR T
The document discusses computed tomography (CT) scanning. It describes the main components of a CT scanner including the gantry, x-ray tube, and detectors. It explains that the gantry houses the x-ray tube and detectors which rotate around the patient to produce cross-sectional images. The document also provides information on the generations of CT scanners and lists some major CT manufacturers and dealers in India.
New developments of targeted therapy in nsclclihua jiao
Targeted therapies have improved outcomes for patients with lung cancer harboring specific mutations. Several studies showed first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) improved response rates and progression-free survival over chemotherapy for patients with EGFR mutations. Resistance often emerges due to the T790M mutation. Irreversible EGFR TKIs like afatinib have shown activity against T790M resistance. Crizotinib demonstrated high response rates and prolonged progression-free survival in patients with anaplastic lymphoma kinase (ALK) rearrangements. New ALK inhibitors are in development. Selumetinib, a MEK inhibitor, showed clinical benefit in patients with KRAS mutations
A tyrosine kinase is an enzyme that transfers a phosphate group from ATP to tyrosine residues on proteins. This phosphorylation regulates protein activity and signal transduction within cells. Tyrosine kinase inhibitors, like nilotinib, are drugs that bind to and inhibit tyrosine kinases. Nilotinib was approved to treat chronic myeloid leukemia and research found it was effective against drug-resistant forms of the disease. It works by binding the inactive form of the Abl kinase to prevent phosphorylation and cancer cell growth.
Dr. Natasha Tiffany has nearly a decade of experience treating cancer patients with targeted therapies as a physician at Hematology Oncology of Salem. Targeted therapy utilizes either antibody drugs that mimic immune system proteins targeting cancer cells or smaller molecule drugs, and has become a major resource in cancer treatment. Some examples of targeted therapy drugs include Gleevec, which is used to treat gastrointestinal stromal tumors and certain leukemias, Iressa for non-small-cell lung cancer with epidermal growth factor receptor mutations, and Sutent and Velcade for kidney cancer and multiple myeloma respectively.
This document discusses tyrosine kinase inhibitors (TKIs), a class of targeted cancer drugs. It begins by introducing protein kinases and their role in cell signaling. There are two main categories of protein kinases - those that phosphorylate tyrosine residues and those that phosphorylate serine and threonine residues. Tyrosine kinases function as on/off switches in many cellular functions by adding phosphate groups to tyrosine residues on proteins. The document then discusses the different types of tyrosine kinases and how they can become mutated and cause unregulated cell growth leading to cancer. It describes targeted therapy and TKIs as targeted drugs that block specific molecules needed for tumor growth. The final sections provide examples of approved TKIs
Integration Of Targeted Therapies With Radiation Lung Cancerfondas vakalis
1) The document discusses integrating targeted therapies such as EGFR inhibitors and angiogenesis inhibitors with chemoradiotherapy for the treatment of stage III non-small cell lung cancer (NSCLC).
2) Several phase II trials showed that combining chemoradiotherapy with the EGFR inhibitor cetuximab was feasible and resulted in promising survival outcomes. This warrants a phase III trial.
3) Combining chemoradiotherapy with tyrosine kinase inhibitors and angiogenesis inhibitors like bevacizumab is also being explored, but data is still limited and complex trial designs make results difficult to interpret. Further research is still needed.
This document discusses tyrosine kinases, which are enzymes that transfer phosphate groups and act as on-off switches in cellular functions. Tyrosine kinases are implicated in cancer development and progression. The document describes the structural classification, general characteristics, and mechanism of action of tyrosine kinases. It also discusses kinetic studies of tyrosine kinases like Bruton's tyrosine kinase and applications of tyrosine kinase inhibitors in cancer therapy and other diseases.
Introduction to Targeted Therapies in OncologyMohamed Abdulla
Describes the molecular background which represents the core for developing targeted therapies against specific biological events in malignant cellular clones.
West egfr mutation acquired resistanceH. Jack West
Review by Dr. H. Jack West of current understanding of mechanisms behind and emerging treatment options for patients with advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors after a good initial response.
Chair, Natasha B. Leighl, MD, MMSc, FRCPC, FASCO, Zofia Piotrowska, MD, and Catherine Shu, MD, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC activity titled “Refining Biomarker Testing and Targeted Treatment of NSCLC With Common and Uncommon EGFR Mutations.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3OAddvR. CME/MOC credit will be available until October 24, 2023.
This document provides a treatment algorithm for NSCLC that is organized by disease stage and biomarker status. It includes recommendations for surgical resection, radiation, chemotherapy, targeted therapies, and immunotherapies at various lines of treatment. Recommended regimens are shown based on factors like mutation status, PD-L1 expression level, and prior therapies. Approvals and indications are also listed for EGFR-targeted therapies in advanced and early-stage, EGFR-mutated NSCLC.
The document summarizes a clinical trial comparing the treatments erlotinib and gefitinib for non-small cell lung cancer. It found that erlotinib improved overall survival compared to standard chemotherapy, with a median survival of 6.7 months for erlotinib versus 4.7 months for chemotherapy. Erlotinib also prolonged progression-free survival compared to chemotherapy. The study provides support for using erlotinib or gefitinib as treatments for non-small cell lung cancer.
EGFR mutations are present in 10-20% of Caucasian and 40-60% of Asian patients with NSCLC. First-generation EGFR TKIs such as gefitinib and erlotinib are the standard of care for patients with EGFR mutations. The FLAURA trial found that the third-generation EGFR TKI osimertinib provided significantly longer progression-free survival compared to gefitinib or erlotinib as a first-line treatment for EGFR mutant NSCLC. Osimertinib also showed benefits for patients with CNS metastases. However, combination of first-generation EGFR TKIs with chemotherapy may provide further benefits in terms of response rate, progression-
Chair & Presenter, David R. Jones, MD, and Nathan A. Pennell, MD, PhD, FASCO, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC activity titled “Adjuvant EGFR-Targeted Therapy as a Game Changer: How to Implement New Standards of Care in Multimodal Management of Stage I-III EGFR-Mutated NSCLC.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3mFfjji. CME/MOC credit will be available until December 2, 2022.
Co-Chairs, Jessica Donington, MD, and Catherine Shu, MD, prepared useful Practice Aids pertaining to NSCLC for this CME activity titled “EGFR-Targeted Therapy for Early-Stage NSCLC: What Thoracic Surgeons Need to Know.” For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at https://bit.ly/3PsMX8N. CME credit will be available until February 21, 2024.
West asco clin mgmt acquired resistance tk isH. Jack West
1) Acquired resistance to targeted therapies like EGFR TKIs in NSCLC can present with heterogeneous clinical patterns from isolated progression to more diffuse progression due to diverse molecular mechanisms.
2) Not all detectable progression requires an immediate treatment change, as some may not represent clinically significant progression. Continuing targeted therapy beyond progression may be reasonable in some cases.
3) For isolated or "oligoprogressive" acquired resistance, local therapy combined with continued targeted therapy is an option. Diffuse progression may warrant switching to chemotherapy, with the potential to later rechallenge with targeted therapy.
4) Prospective randomized trials are needed to define optimal treatment approaches for acquired resistance, and trials of novel agents could help special populations.
Edward S. Kim, MD, FACP, prepared useful practice aids pertaining to EGFR mutation-positive advanced NSCLC in this CME/MOC/CNE/CPE activity titled "Beyond Clinical Trials: Can Real-World Evidence Provide a Roadmap for Long-Term Treatment Planning in EGFR Mutation-Positive NSCLC? Data-Driven Guidance on Patient Selection, Therapeutic Sequencing, and Tailored Use of Expanding Options." For the full presentation, downloadable practice aids, monograph, complete CME/MOC/CNE/CPE information, and to apply for credit, please visit us at http://bit.ly/2AYGddF. CME/MOC/CNE/CPE credit will be available until January 31, 2019.
Co-Chairs Roy S. Herbst, MD, PhD, and Lecia V. Sequist, MD, MPH, prepared useful Practice Aids pertaining to EGFR-mutated lung cancer for this CME activity titled “New Milestones and Changing Standards of Care in EGFR-Mutated NSCLC: Expanding the Benefits of Genomic Testing and EGFR-Targeted Therapy to Early-Stage Lung Cancer.” For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at http://bit.ly/36aVo39. CME credit will be available until March 8, 2022.
Maria Arcila, MD, Zofia Piotrowska, MD, and Joshua Bauml, MD, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC/CC activity titled “New Horizons in EGFR-Mutated NSCLC: Broadening the Impact of Precision Testing in the Context of an Expanding Treatment Landscape.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/CC information, and to apply for credit, please visit us at https://bit.ly/3kH1ygr. CME/MOC/CC credit will be available until January 25, 2022.
David R. Jones, MD, and Roy S. Herbst, MD, PhD, prepared useful practice aids pertaining to lung cancer for this CME activity titled "Turning Tides in Targeted Therapy for Early-Stage EGFR-Mutated NSCLC: Latest Data and Practical Guidance for Thoracic Surgeons and the Multidisciplinary Team on the Emerging Role of EGFR-Targeted Therapy in Resectable Lung Cancer." For the full presentation, complete CME information, and to apply for credit, please visit us at https://bit.ly/2PSVELG. CME credit will be available until November 9, 2021.
This presentation provides an overview of the standard of care and new advances in the treatment of high-grade glioma, specifically glioblastoma multiforme (GBM) and anaplastic astrocytoma. The key points discussed include:
- The current standard of care for GBM is maximal safe surgical resection followed by concurrent radiation therapy and temozolomide chemotherapy, then adjuvant temozolomide.
- The landmark EORTC/NCIC trial established temozolomide combined with radiation as the standard of care, improving median survival from 12 to 14.6 months.
- MGMT promoter methylation status is the strongest predictor of outcome, with methylated tumors responding better
A cancer that begins in the lungs and most often occurs in people who smoke.
Two major types of lung cancer are non-small cell lung cancer and small cell lung cancer. Causes of lung cancer include smoking, second-hand smoke, exposure to certain toxins and family history.
Symptoms include a cough (often with blood), chest pain, wheezing and weight loss. These symptoms often don't appear until the cancer is advanced.
Treatments vary but may include surgery, chemotherapy, radiation therapy, targeted drug therapy and immunotherapy.
3.Case Based Moderation Slidedeck 110_130_150.pptxBipineshSansar
This document discusses treatment options for patients with metastatic non-small cell lung cancer (NSCLC) without driver mutations. First-line options include cancer immunotherapy (CIT) monotherapy, CIT plus chemotherapy, CIT plus chemotherapy plus anti-VEGF. Second-line options include chemotherapy, CIT doublet, or anti-angiogenic plus chemotherapy. CIT is not an option in later lines if already given in earlier lines. The document also discusses predictive biomarkers for CIT efficacy and immune checkpoint inhibitors.
Chair and Presenters Sandip Patel, MD, Tina Cascone, MD, PhD, and John V. Heymach, MD, PhD, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC activity titled “The “Immunosurge” Continues: Moving in Leaps and Bounds to Expand the Role and Impact of Immunotherapy in Metastatic, Locally Advanced, and Early-Stage NSCLC.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3u3mUP5. CME/MOC credit will be available until March 22, 2025.
1) The document discusses optimal practice in radiation treatment for head and neck cancer in the 21st century, focusing on balancing treatment targets and sparing normal tissues using available technology and expertise.
2) It reviews treatment options and approaches for different stages of head and neck cancer, highlighting evidence that altered fractionation and chemoradiation can improve outcomes over standard radiation alone.
3) Challenges of implementing intensity-modulated radiation therapy (IMRT) for head and neck cancer are discussed, as well as examples of how IMRT can improve target coverage and tissue sparing compared to conventional techniques.
Similar to Acquired resistance to EGFR TKIs in Lung Cancer (NSCLC) (20)
Moving Beyond the Hype: 3 Key Steps for Personalized Cancer MedicineH. Jack West
The concept of personalized or precision medicine is hot enough that President Obama is launching initiatives for it, but how close is it to moving beyond hype?
Here are 3 key steps we need to attain to know that personalized medicine, particularly in the world of cancer care, isn't just delivering false hope for most patients.
This document summarizes the top five highlights in lung cancer in 2014. They are:
1) CMS approved low-dose CT screening for high-risk patients, which could improve early detection and survival rates for lung cancer.
2) New targeted therapies were approved that can overcome resistance for EGFR and ALK-positive NSCLC, including ceritinib for ALK resistance and AZD9291 and rociletinib for EGFR T790M mutation resistance.
3) New treatments provided small survival benefits of around 1.5-2 months for broad populations of previously treated advanced NSCLC, including Cyramza and nintedinib.
4) Immune checkpoint inhibitors like PD-1
Best of ASCO Metastatic Non-Small Cell Lung CancerH. Jack West
Dr. Jack West's presentation on highlights in advanced non-small cell lung cancer from ASCO 2014, focusing on new agents ramucirumab and necitumumab for broad NSCLC populations, crizotinib and ceritinib for ALK-positive NSCLC, EGFR inhibitor-options of afatinib and bevacizumab added to erlotinib for first line treatment of EGFR mutation-positive NSCLC, and AZD9291 or CO1686 for EGFR mutation-positive patients with acquired resistance.
10 Key ASCO 2014 Presentations in Lung CancerH. Jack West
Dr. Jack West offers a list of 10 of the most important, timely abstract presentations in lung cancer, both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), at the annual ASCO 2014 conference.
Transitioning Survival from Months to Years in Advanced Non-Small Cell Lung C...H. Jack West
Dr. Jack West reviews the evolution of new treatment options for advanced NSCLC that have steadily improved survival. This progress has been incremental but now means that an ever-growing proportion of patients with advanced NSCLC have a realistic promise of potentially living several years after their diagnosis and the start of treatment. Note that this presentation does not address advances in immunotherapy, which were covered in a separate talk at the same conference at which Dr. West delivered this presentation.
What is the value of maintenance therapy in advanced NSCLC, and who should ge...H. Jack West
Dr. Jack West reviews the rationale for maintenance therapy in advanced NSCLC, what the evidence shows about its value, the limitations, and thoughts on which patients should or should not pursue it.
50 Shades of Cancer Progression: The Continuum of Progression & How We Decide...H. Jack West
Dr. Jack West reviews the importance of assessing the degree of progression when interpreting whether to change treatment of a cancer. It is important to ask not only whether a cancer has progressed, but HOW it has done so, and how much?
Key Clinical Implications of how a Cancer EvolvesH. Jack West
Cancer adapts and evolves over time and under the selective pressure of systemic treatment, becoming increasingly resistant over time. This brief slidedoc fo summarizes key points in how cancer adaptation leads to resistance and changes our treatment recommendations.
Treating Invisible Disease: How the Probability of Disease We Can't See Chang...H. Jack West
A brief slidedoc that reviews why we focus on both the cancer we can see and the potential cancer we can't when we shape our treatment recommendations in lung cancer and many other cancers.
Changes Afoot: Changing Relationships between Engaged Patients and Docs in Ca...H. Jack West
Discussion of how online patient communities and social media are changing relationships between engaged patients and oncologists, improving quality of cancer care.
Patient and doc engagement online westH. Jack West
The document discusses how the relationship between doctors and patients is changing from a unidirectional model to a bidirectional model due to the increasing amount of medical information available online. It notes that the rate of new medical information has more than doubled in the last 20 years, making it impossible for doctors to know everything. As a result, patients are increasingly informed and motivated to help themselves by seeking information from social networks and online resources. This is shifting the interaction between doctors and patients to a more collaborative bidirectional model where physicians are no longer expected to have all the answers and patients play a more active role in their own care.
West Immunotherapy, Vaccines for Lung Cancer Mage-A3, Stimuvax, and LucanixH. Jack West
This document summarizes information about three cancer vaccines - MAGE-A3, Stimuvax (L-BLP25, Tecemotide), and Lucanix (Belagenpumatucel-L). It discusses past and ongoing clinical trials of these vaccines in non-small cell lung cancer (NSCLC), including trial designs, results, and potential efficacy in patient subgroups. Key information presented includes Phase 3 trial results for Stimuvax showing a possible survival benefit in patients receiving concurrent chemotherapy and radiation, and evidence that Belagenpumatucel-L may benefit certain NSCLC patient subgroups based on retrospective analyses.
Dr. Jack West Oncology 2.0, to WA AG's OfficeH. Jack West
Dr. H. Jack West, medical oncologist and Founder/CEO of Global Resource for Advancing Cancer Education (GRACE, www.CancerGRACE.org), spoke to WA state Attorney General's office about the changing landscape of cancer care and how the internet and specifically online patient communities and education will become disruptive in changing the patient/physician dynamic.
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...Donc Test
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler Community Health Nursing A Canadian Perspective, 5th Edition TEST BANK by Stamler Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Study Guide Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Studocu Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Course Hero Community Health Nursing A Canadian Perspective, 5th Edition Answers Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Course hero Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Studocu Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Study Guide Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Ebook Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Questions Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Studocu Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Stuvia
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Acquired resistance to EGFR TKIs in Lung Cancer (NSCLC)
1. How Do We Manage Acquired Resistance
to EGFR TKI Therapy?
Howard (Jack) West, MD
Swedish Cancer Institute
Seattle, WA
Challenging Cases
in Breast & Lung Cancer
Las Vegas, NV
April 21, 2012
3. T790M Mutation
• Most common mechanism of resistance to EGFR
TKIs (50-68%)
• May have a better prognosis than non-T790M
mechanisms: 19 vs. 12 mo post-progression, Oxnard, CCR
2010
N = 93
• T790M more likely to show
progression in lungs/pleura
• Non-T790M more likely to
progress distantly, & worse PS
4. Rapid Progression with Discontinuation of
EGFR TKI after Prolonged PFS
Rapid acceleration of disease progression resulting
in hospitalization and/or death after discontinuation of
gefitinib or erlotinib and before initiation of study drug
(up to ~1/4 of pts in MSKCC series (Chaft, CCR,
2011)
Last day of TKI Off EGFR TKI Resumed TKI
Day 0 Day 21 Day 42
From Riely, CCR 2007
5. For Cancers with a Known Driver Mutation, Continuing
Inhibition of that Target is Beneficial after Progression
• Progression of CML on imatinib increase dose, or dasatinib, or
nilotinib lead to consistent response
• Solid tumor example: HER2+ breast cancer
Minckwitz, JCO 2009
6. Such Patients Often Show
Slow, Modest Progression
Brakes may not be as good, but better than no brakes
No change in therapy may be needed initially
7. Combining Systemic and Local Targeted Therapies:
Radiation (or Surgery) to Isolated Area of Progression
Survival after RT to 1-2 sites of Freedom from Locoregional
metastatic disease (Lung Ca) Recurrence after Chest RT
1.0
0.9
Freedom from Locoregional Recurrence
EGFR mutation
0.8
0.7
0.6
0.5
0.4
EGFR wild type
0.3
0.2
0.1
0.0
0 12 24 36 48 60 72 84 96 108
Time (months)
Kahn, Radiotherapy & Oncology, 2006 Mak, ASCO 2010, A#7016
Perhaps extend the idea of the “precocious metastasis” to
“precocious recurrence”
9. Irreversible TKIs in Clinical Trials
• HKI-272 (EGFR + Her2)
• RR 2% in TKI-resistant patients
• Intriguing responses in G719X patients (Sequist, JCO 2010)
• XL-647 (EGFR, Her2, VEGF)
• RR 2% in TKI-resistant patients (Pennell, Chicago Lung ’08)
• PF-299804 (EGFR + Her2)
• RR 7% in TKI-resistant patients (Janne, ASCO ’09)
• BIBW-2992 (EGFR + Her2)
• RR 7% in TKI-resistant pts, 2 mo PFS increase (Miller, ESMO’10)
• Interesting ongoing study combining afatinib and cetuximab based on
a mouse model that was successfully treated w/ this combo
10. LUX Lung 1
• Does Afatinib work in patients with acquired resistance
to first generation EGFR TKI?
Patients with:
• Adenocarcinoma of the lung
• Stage IIIB/IV
• Progressed after one or two lines of chemotherapy (incl. one platinum-based regimen) and ≥12 weeks of
treatment with erlotinib or gefitinib
• ECOG 0–2
N=585
Randomization
2:1
Oral BIBW 2992 50 mg once daily Oral placebo once daily
plus best supportive care plus best supportive care
Primary endpoint: Overall survival (OS)
Secondary: PFS, RECIST response, QoL, safety
12. Implication of LUX Lung1
• Lack of OS
– OS of 11.9 months in Placebo group
• Suggestive evidence of efficacy:
– RR at 13.3% and PFS (HR 0.38)
• Relationship to T790M not known
• Future implication
– Biomarker selection
– Combination with cetuximab
13. Afatinib/Cetuximab in
EGFR TKI-Resistant NSCLC
Dose escalation schema
NSCLC w/ 3-6 patients per cohort
EGFR mut’n1
and PD2
afatinib p.o. daily + escalating doses of
SD ≥ 6 mo on Stop EGFR TKI cetuximab IV q 2 weeks
erlotinib/gefitinib For ≥ 72 hours3
or Dose levels starting at:
CR or PR afatinib 40 mg +
to erlotinib/gefitinib cetuximab 250 mg/m2
Predefined maximum dose:
afatinib 40mg +
cetuximab 500 mg/m2
1
EGFR G719X, exon 19 deletion, L858R, L861Q
2
Progression of disease (RECIST v1.1) on continuous
treatment with erlotinib or gefitinib within the last 30 Expansion cohort part4
days. MTD cohort expanded
3
Amended from original 14 days interval up to 80 EGFR mutation-positive patients:
4
Acquisition of tumor tissue after the emergence of
40 T790M-positive and 40 T790M-negative
acquired resistance was mandated
Jangigian & Pao, ASCO 2011, #7525
14. Afatinib + Cetuximab at MTD:
Responses by EGFR Mutation
40% confirmed response rate and a clinical benefit rate of 90%
Jangigian & Pao, ASCO 2011, #7525
15. Afatinib + Cetuximab:
Insights & Future Directions
• Remarkable efficacy seen in EGFR TKI-
resistant tumors
– Requires further validation
• Activity not specific to common T790M mutant
• Need to further define biology and refine patient
population for phase III trial
17. Met Inhibitors in Clinical Trials
• ARQ-197, specific MET inhibitor
– Randomized phase II of erlotinib +/- ARQ-197 in TKI-naïve patients
showed some benefit of combo but wasn’t designed to look at EGFR
mutants or acquired resistance to EGFR TKIs (Schiller, ASCO 2010)
• Met-Mab
– Randomized phase II of erlotinib +/- MET-Mab in TKI-naïve pts
showed benefit of combo, but again wasn’t designed to look at EGFR
mutants or acquired resistance to EGFR TKIs (Spigel , ASCO 2011
• XL-184, MET + RET + VEGF
– Randomized phase II of erlotinib +/- XL-184 in TKI-resistant patients,
completed but not reported yet
• PF-02341066:
– Still in early phase studies
18. MetMAb is an anti-Met Monovalent
Antibody that Inhibits HGF-MediatedActivation
Rationale for targeting Met:
HGF HGF • Met is amplified, mutated,
overexpressed or uniquely activated
in many tumors
MetMAb • Met expression is associated with
worse prognosis in many cancers
including NSCLC
Met Met
• Met activation is implicated in
resistance to erlotinib/gefitinib in pts
with activating EGFR mutations
MetMAb:
Growth No
Migration activity • One-armed format designed to
Survival prevent HGF-mediated stimulation
of pathway
HGF: Hepatocyte growth factor • Preclinical activity across multiple
Spigel, ASCO 2011, #75051 tumor models
19. Randomized Phase II: Erlotinib + MetMAb
or Placebo in 2nd/3rd line NSCLC
Stage IIIB/IV NSCLC N = 69
2nd/3rd line Erlotinib 150 mg PO daily
Tissue required R MetMAb 150 mg/kg IV Q3wk
PS 0–2 A
Stratification factors: N
•Tobacco history
•Performance status
D Erlotinib 150 mg PO daily
•Histology Placebo IV Q3wk
N = 68
N = 137
PD
N = 27
Co-primary objectives: Other key objectives:
• PFS in ‘Met Diagnostic • OS in ‘Met Diagnostic positive’ add MetMAb
positive’ patients (est. 50%) patients Must be eligible to be
• PFS in overall ITT population • OS in overall ITT patients treated with MetMAb
• Overall response rate
• Safety/tolerability
Spiegel, ASCO 2011, #7505
20. Development of Met IHC for
Use as a Companion Diagnostic
• Technical metrics
– Tissue was obtained from 100% of patients.
– 93% of patients had adequate tissue for evaluation of Met by IHC
• Intensity of Met IHC staining on NSCLC tumor cells scored in 4 categories
Met Dx Met Dx Positive
1000 Negative
MET mRNA (2-∆ct)
Negative (0) Weak (1+)
100
Met Dx
Negative 10
1
Moderate (2+) Strong (3+)
Met Dx 0
Positive 0 1 2 3
MET IHC score
• Met diagnostic status was assessed after randomization and prior to unblinding
– ‘Met Diagnostic Positive’ was defined as majority (≥50%) of tumor cells with moderate or strong staining intensity
52% patients enrolled were ‘Met Diagnostic Positive’
Spiegel, ASCO 2011, #7505
21. Erlotinib + MetMAb or Placebo
in 2nd/3rd line NSCLC: Safety
Met Diagnostic Positive Met Diagnostic Negative
No.of patients (%) MetMAb +
Placebo + erlotinib MetMAb + erlotinib Placebo + erlotinib
erlotinib
(n=31) (n=35) (n=31)
(n=31)
Any adverse event 31 (100) 35 (100) 31 (100) 31 (100)
Grade ≥3 adverse
17 (54.8) 20 (57.1) 13 (41.9) 17 (54.8)
event
Serious adverse
11 (35.5) 15 (42.9) 9 (29.0) 13 (41.9)
event
Adverse events
leading to treatment 2 (6.5) 8 (22.9) 0 (0) 2 (6.5)
discontinuation
Adverse events
4 (12.9) 1 (2.9) 0 (0) 3 (9.7)
leading to death
Spiegel, ASCO 2011, #75051
22. Erlotinib + MetMAb or Placebo:
Efficacy in ITT Population
PFS: HR=1.09 OS: HR=0.8
Placebo + MetMAb + Placebo + MetMAb +
erlotinib erlotinib erlotinib erlotinib
Median (mo) 2.6 2.2 Median (mo) 7.4 8.9
1.0 HR 1.09 1.0 HR 0.80
Probability of progression free
(95% CI) (0.73–1.62) (95% CI) (0.50–1.3)
Log-rank p-value 0.69 Log-rank p-value 0.34
Probability of survival
0.8 No. of events 56 48 0.8 No. of events 41 34
0.6 0.6
0.4 0.4
0.2 0.2
Note: + = censored value. Note: + = censored value.
0.0 0.0
0 3 6 9 12 15 18 0 3 6 9 12 15 18 21
Time to progression (months) Overall survival (months)
Control arm was consistent with previous studies in a similar population
(Br21 PFS 2.2 mo, OS 6.7 mo, ORR 8.9%)
Spigel, ASCO 2011, #75051
23. Erlotinib + MetMAb or Placebo: Efficacy
in Met Diagnostic Positive NSCLC Patients
PFS: HR=0.53 OS: HR=0.37
Placebo + MetMAb + Placebo + MetMAb +
erlotinib erlotinib erlotinib erlotinib
Median (mo) 1.5 2.9 Median (mo) 3.8 12.6
1.0 HR 0.53 1.0 HR 0.37
(95% CI) (0.28–0.99) (95% CI) (0.19–0.72)
Probability of progression free
Log-rank p-value 0.042 Log-rank p-value 0.002
0.8 No. of events 27 20 0.8 No. of events 26 16
Probability of survival
0.6 0.6
0.4 0.4
0.2 0.2
0.0 0.0
0 3 6 9 12 15 18 0 3 6 9 12 15 18 21
Time to progression (months) Overall survival (months)
The addition of MetMAb to erlotinib doubled the progression free survival
and nearly tripled the overall survival in this population
Spigel, ASCO 2011, #75051
24. ARQ-197: c-MET Receptor Tyrosine Kinase
• Implicated in tumor cell migration,
invasion, proliferation, and angio-
genesis1
• Only known high-affinity receptor for
hepatocyte growth factor (HGF)1
• c-MET amplification associated with:
• Poor prognosis in NSCLC2
• Resistance to EGFR TKIs3,4
1. Birchmeier C and Gherardi E. Trends Cell Biol 1998;8:404–10
2. Cappuzzo F et al. JCO 2009;27:1667–74
3. Engelman JA et al. Science 2007;316:1039–43
4. Bean J et al. PNAS 2007;104:20932–7
25. Rand Phase II: Erlotinib + Tivantinib (ARQ-197)
or Placebo in Prev Treated Adv NSCLC
Inop Loc Adv/Met NSCLC
>1 prior line of Rx N = 84 Erlotinib 150 mg PO daily
No prior EGFR TKI R ARQ-197 360 mg PO BID
PS 0–2 A
Stratification factors:
sex, age, ECOG PS, N
smoking status, histology, D Erlotinib 150 mg PO daily
prior Rx, best response, & Placebo PO BID
geography (U.S. vs. ex- N = 83
U.S.) PD
N = 167 N = 21
Endpoints
add ARQ-197
• 1° PFS
• 2° ORR, OS
• Subset analyses
Sequist, JCO 2011 • Crossover: ORR
31. Research Efforts for
Acquired Resistance to EGFR TKIs
• Afatinib/cetuximab looks very promising
• Unexpectedly, not correlated with T790M
• Phase III trial in development
• MetMAb phase II trial encouraging in subset
• Benefit appears limited to high Met expression
(detrimental in low Met expression)
• Phase III trial in development
• Tivantinib phase II trial favorable, esp in non-squamous
• Phase III trial now ongoing
• Possibly particularly helpful for KRAS mut’n positive
• Increasing interest in post-PD biopsies, though not yet
useful outside of trial setting
32. Acquired Resistance to EGFR TKIs:
Practical Principles for the Clinic
• Patients can respond to EGFR TKI with rechallenge,
especially after long interval off of EGFR TKI (breaks
onc rule of “you can never go back”
• ?Consider local therapy to solitary area of PD
• Some patients will have a rebound rapid progression
after being taken off of an EGFR TKI
• Heterogeneous populations of cancer cells
• Is it better to continue the EGFR TKI and add an
agent/regimen, or to stop it and potentially restart it later??
• I favor continuing EGFR TKI when PD < PR, but not
when PD is very clear
• No comparison and no good data to address this
Editor's Notes
-Met is a Receptor tyrosine kinase. -Following binding to its only known ligand, hepatic growth factor, Met receptors dimerize, leading to growth, migration and survival signals -Met is amplified, mutated, over-expressed or uniquely activated in many tumors -Expression of Met is associated with worse prognosis in NSCLC; additionally aberrant Met activation results in resistance to EGFR inhibitors -MetMAb is a unique one-armed antibody, designed to prevent HGF-mediated signaling
Methodology CONFIRM anti-total Met, as per manufacturer’s instructions Run on Ventana Benchmark instrument at GNE Negative controls (isotype control) performed on each specimen Positive controls (cell pellets) included on every run